FIELD: pharmaceuticals.
SUBSTANCE: invention relates to (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or salt thereof. Also provided is a drug having a tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) inhibitory effect, containing as the active ingredient (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.
EFFECT: obtained is a novel compound and a pharmaceutical agent based on it that can be used in medicine for the treatment of psoriasis.
20 cl, 3 tbl, 1 ex
Authors
Dates
2018-09-27—Published
2014-06-06—Filed